Gene synthesis: which startup is ahead?
In our synthetic biology market deck, you will find everything you need to understand the market
SUMMARY
Elegen is the gene synthesis startup ahead today, with Ansa Biotechnologies close behind and gaining ground faster.
The top two lead for different reasons. Elegen has made long synthetic DNA easier to buy, while Ansa has pushed the technical ceiling much further with sequence-verified constructs reaching 50 kb.
That split matters more than the headline ranking. Elegen is the stronger supplier for a broad customer base; Ansa is the better answer when the sequence is unusually long, repetitive or simply beyond the range of normal providers.
DNA Script belongs in the top three, but it is playing a different game. Its SYNTAX machines make short oligonucleotides inside the customer’s lab, so the customer gains speed and control but still has to assemble and verify a complete gene.
Funding has not translated neatly into leadership. DNA Script has raised about $315 million, yet Elegen and Ansa have created broader finished-DNA offers with much less disclosed capital.
Elegen’s price reduction to roughly $0.07 per base pair is one of the strongest pieces of commercial evidence in the field. It suggests that manufacturing improvements are reaching customers rather than remaining inside a development laboratory.
Ansa has the clearest momentum. Its longer product range, $54.4 million manufacturing raise, delivery guarantee and IDT distribution agreement all point in the same direction: turning an exceptional technical platform into a larger commercial operation.
The quality comparison is less tidy than company marketing makes it look. Elegen’s per-base accuracy, Ansa’s sequence-perfect clone verification and Ribbon Bio’s share of sequence-correct molecules describe different outputs and should not be ranked as though they were the same test.
IDT’s distribution deals with both Elegen and Ansa are a useful clue about where the market may go. The startups provide capabilities that established suppliers want quickly; the incumbents provide the sales reach, purchasing relationships and support infrastructure the startups cannot build overnight.
The ranking can still change. Ansa could overtake Elegen if its new capacity produces reliable volume and competitive turnaround, while Ribbon Bio has a credible route into the top three if its 12 kb cell-free products and in-lab kit gain visible adoption.
For now, Elegen leads the business, Ansa leads the technical frontier, DNA Script leads decentralized oligo synthesis, and the rest of the field is still proving that strong chemistry can become repeatable commercial delivery.
This market map, featured in our synthetic biology market deck, highlights top companies and startups in the synthetic biology market
Which gene synthesis startups belong in this comparison?
The gene synthesis startup field currently has six serious companies, but only Elegen, Ansa Biotechnologies and Ribbon Bio publish enough product detail to show finished multi-kilobase DNA at a scale that can be compared cleanly.
We include Elegen, Ansa Biotechnologies, DNA Script, Ribbon Bio, Camena Bioscience and Evonetix because custom DNA production sits at the center of their technology and business models. Elegen, Ansa and Ribbon deliver finished synthetic DNA. DNA Script sells an instrument that produces short oligonucleotides inside the customer’s laboratory. Camena supplies complex genes through its gSynth platform. Evonetix is developing a semiconductor-based benchtop writer but has yet to release a broadly available product.
We exclude Twist Bioscience, GenScript and Integrated DNA Technologies because they are established suppliers rather than startups. Telesis Bio is publicly traded. Molecular Assemblies is no longer independent after Maravai LifeSciences acquired its intellectual property and related assets. EnPlusOne focuses on RNA, while Biomemory mainly develops DNA data storage.
Funding totals require caution because databases often mix equity, grants, debt and committed capital. We use disclosed equity rounds where possible and describe uncertain totals as approximate.
| Startup | What it does | Cumulative funding |
|---|---|---|
| DNA Script | Benchtop enzymatic production of short DNA oligonucleotides | $315 million |
| Ansa Biotechnologies | Enzymatic synthesis and assembly of clonal DNA up to 50 kb | About $130 million in disclosed equity rounds |
| Evonetix | Semiconductor-based benchtop gene synthesis platform in development | About $68–70 million |
| Elegen | Cell-free production of linear DNA, plasmids and IVT-ready templates | At least $35 million publicly disclosed |
| Ribbon Bio | Cell-free production of complex linear and circular DNA | About $20 million publicly documented |
| Camena Bioscience | TdT-free enzymatic production of complex synthetic genes | $10 million disclosed, plus later undisclosed capital |
Which gene synthesis startup is ahead right now?
Elegen is ahead in gene synthesis today because it combines a real commercial product, fast delivery, clear pricing and production that has already moved beyond pilot scale.
Ansa is close behind and already leads on the longest and most difficult DNA constructs. The difference is that Elegen currently makes the easier buying decision for a wider group of customers. Researchers can order standardized linear DNA, plasmids and IVT-ready templates with published specifications and predictable turnaround times.
Elegen’s latest manufacturing platform has entered full commercial production. That has allowed the company to reduce prices while keeping delivery for its core linear DNA product at roughly six to eight business days. It also has major pharmaceutical and distribution relationships that put its products in front of customers without requiring Elegen to build every sales channel itself.
Ansa’s technical offer is more ambitious. It sells sequence-verified fragments, clonal constructs and ultra-long DNA that few competitors will even attempt. Its recent manufacturing raise and delivery guarantee show that the company is now trying to turn that technical lead into a larger commercial business.
The gap is real but narrow. We would place Elegen at 100 on overall execution today and Ansa around 85. DNA Script would sit much lower in complete-gene delivery because its commercial machine still produces short oligonucleotides rather than finished genes.
If you want more recent data on this point, please see our latest synthetic biology market report.
As this chart shows, and as featured in our synthetic biology market deck, search interest in gene editing has grown significantly
Which gene synthesis startup has the most mature product?
Elegen has the most mature complete-gene product line, while DNA Script leads the separate market for commercial benchtop oligonucleotide synthesis.
Elegen publishes the details buyers need before placing an order: supported lengths, expected turnaround, accuracy, formats and pricing. Its catalogue now covers linear DNA, plasmid DNA and templates prepared for in vitro transcription. That breadth makes Elegen look like a supplier with a working product family, not a platform still searching for its first use case.
Ansa is also fully commercial. Customers can buy short fragments, standard clonal constructs and much longer custom sequences. Its products are technically mature, although the company is still expanding the manufacturing capacity needed to handle larger order volumes.
DNA Script’s SYNTAX instrument is already installed in laboratories and can produce hundreds of short oligonucleotides in parallel. The product is real and differentiated, but customers who need a full gene must still assemble and verify those oligonucleotides afterward.
Ribbon has launched both linear and circular cell-free DNA and is testing an in-lab synthesis kit. Camena supplies genes through selected partnerships, but it publishes fewer standard product specifications. Evonetix remains pre-commercial.
| Startup | Product stage | What customers can obtain now |
|---|---|---|
| Elegen | Full commercial production | Linear DNA, plasmids and IVT-ready templates |
| Ansa | Commercial and expanding capacity | Fragments and clonal DNA across a very wide length range |
| DNA Script | Commercial instrument | Up to 384 short oligonucleotides per run |
| Ribbon Bio | Early commercial expansion | Cell-free linear or circular DNA and a beta in-lab kit |
| Camena Bioscience | Partner-led commercialization | Custom genes through selected commercial programmes |
| Evonetix | Pre-commercial development | No broadly available gene synthesis product |
Which gene synthesis startup can deliver the longest DNA?
Ansa is clearly ahead on DNA length, with sequence-verified clonal constructs reaching 50 kb.
That maximum is more than three times the length of Elegen’s longest published plasmid offer and more than four times Ribbon Bio’s 12 kb range. The gap opens use cases that smaller constructs cannot handle, including full metabolic pathways, large gene-therapy payloads and substantial genomic regions.
Ansa does not write all 50,000 bases in one uninterrupted reaction. Its platform directly synthesizes difficult segments, then assembles, amplifies and verifies the final molecule. Customers still receive the finished construct they ordered, so the distinction matters scientifically more than commercially.
Elegen’s main linear product reaches 7 kb, while longer plasmid formats extend to around 15 kb. Ribbon produces cell-free DNA from roughly 700 base pairs to 12 kb. DNA Script’s commercial instrument produces much shorter oligonucleotides, although the company also offers specialized outsourced sequences beyond the normal instrument range.
Camena says gSynth can handle DNA of almost any length and complexity, but it has not published a standard maximum that can be compared properly. Evonetix still describes gene-length synthesis as a development target.
For a customer whose main problem is getting one very large construct made, Ansa is in a class of its own among startups.
This chart, featured in our synthetic biology market deck, illustrates yearly VC funding for synthetic biology startups
Which gene synthesis startup delivers DNA fastest?
Elegen gives most customers the fastest route to a complete multi-kilobase gene, while DNA Script is much faster when the customer only needs short oligonucleotides.
Elegen delivers its standard linear DNA in roughly six to eight business days. Ansa starts around four business days for short fragments, but standard clonal constructs take longer and its largest products require several weeks.
DNA Script can make oligonucleotides inside a laboratory within hours. A short run may finish in about six hours, while longer sequences can take close to a day. That speed is useful for primers, assay development, CRISPR experiments and rapid design changes.
The difference is what comes out at the end. DNA Script gives the researcher building blocks. Elegen and Ansa give the researcher a finished construct. Once assembly, cloning and verification are added, the same-day advantage can disappear for anyone who needs a full gene.
Ansa has added an on-time guarantee for qualifying orders, with the order provided free if it misses the promised delivery window. It does not make Ansa the fastest supplier, but it gives customers more protection against the delays that often affect difficult sequences.
Which gene synthesis startup delivers the best DNA quality?
Elegen publishes the strongest quantitative quality claim, while Ansa gives customers the clearest promise of a sequence-perfect verified clone.
Elegen reports 99.999% per-base accuracy for its NGS-verified linear DNA, equivalent to about one error per 70,000 bases. Ansa verifies the final clonal construct against the requested sequence. Ribbon says at least 90% of molecules are sequence-correct across products reaching 12 kb.
Those numbers measure different things. Elegen reports errors across the delivered DNA population. Ansa checks that the selected clone matches the requested design. Ribbon measures the proportion of correct molecules already present in a cell-free batch.
The best choice depends on how the DNA will be used. A researcher who needs one confirmed clone may prefer Ansa’s straightforward verification model. A customer using the DNA population directly for in vitro transcription may care more about Elegen’s error rate or Ribbon’s proportion of correct molecules.
No recent independent study has sent the same large set of difficult sequences to all three companies and compared accuracy, usable yield and delivery success under identical conditions. We can rank the transparency of their claims more confidently than their absolute laboratory performance.
This chart, featured in our synthetic biology market deck, shows how Twist Bioscience is capturing share in synthetic biology
Which gene synthesis startup handles difficult sequences best?
Elegen and Ansa are the two strongest startups for DNA that is repetitive, unstable, toxic or unusually rich in GC content.
Elegen’s cell-free process avoids growing every sequence inside bacteria. That removes a common source of failure because toxic or unstable DNA can be deleted, rearranged or selected against during bacterial cloning. The company explicitly accepts repeats, homopolymers, viral terminal repeats and other designs that conventional providers often reject.
Ansa tackles the same problem earlier in the workflow. Its enzyme-based chemistry can directly synthesize unusually long complex segments before they are assembled into the final construct. That gives Ansa more freedom with highly structured, repetitive and extreme-GC sequences.
Ribbon also uses a cell-free process and targets unstable or biologically toxic DNA. Its platform is credible, but fewer customer examples and comparative results are publicly available.
Camena may become a stronger competitor here. Its gSynth platform combines enzymatic synthesis, software-based design and parallel assembly without depending on the TdT enzyme used by several rivals. The company says this reduces the need to redesign difficult biological sequences just to make manufacturing easier.
The missing number is first-pass success rate. None of the leading startups clearly discloses what percentage of submitted customer designs it accepts and delivers without redesign. Until that changes, Elegen and Ansa share the lead.
If you want more recent data on this point, please see our latest synthetic biology market report.
Which gene synthesis startup offers the best price?
Elegen currently offers the clearest and most aggressive published pricing in startup gene synthesis, with verified linear DNA starting around $0.07 per base pair.
At that rate, the sequence component of a 1,000-base-pair order would begin near $70, while 7,000 base pairs would cost roughly $490 before minimum charges, format choices, shipping or sequence-complexity adjustments.
The bigger story is the drop from Elegen’s earlier price of roughly $0.15 per base pair. A reduction of more than half suggests that the company has improved throughput, yield or reagent use enough to pass some of the savings to customers.
Ansa does not publish enough standard pricing to support a broad comparison. Ribbon gives sequence-specific quotations because complexity and length can change manufacturing cost sharply. DNA Script also keeps instrument and reagent prices private, making its economics depend heavily on laboratory usage.
A busy laboratory may save time with DNA Script by producing short sequences internally. A laboratory that runs the machine occasionally may spend less by outsourcing. Ansa may offer excellent value for a very large construct that others cannot make, but that is a capability advantage rather than a demonstrated price lead.
For normal multi-kilobase orders with publicly visible terms, Elegen is the price benchmark today.
This chart, featured in our synthetic biology market deck, illustrates yearly funding for synthetic biology startups
Which gene synthesis startup has the strongest commercial traction?
Elegen has the strongest commercial traction among gene synthesis startups because its product launches, production changes and customer partnerships all point to repeated paid use.
The clearest evidence comes from Elegen’s move into full commercial production, its expanding catalogue and its decision to lower prices. Companies usually cut prices after improving manufacturing or expecting enough volume to compensate for the lower revenue per order.
GSK adds another layer of credibility. The pharmaceutical company has worked with Elegen, licensed aspects of its technology and invested in the business. That combination suggests deeper technical interest than a normal research collaboration.
Elegen also distributes long and complex DNA through IDT. This gives the startup immediate access to laboratories that already buy synthetic DNA from an established supplier. In practical terms, a customer can encounter Elegen’s product through a company it already knows rather than discovering a small startup from scratch.
Ansa is closing the gap. It has raised capital to expand US production, introduced delivery guarantees and reached its own distribution agreement with IDT. Revenue and order volumes remain undisclosed, so we cannot say how close the two companies are financially.
DNA Script has commercial instruments and recently expanded distribution across Asia and Latin America. The company has not published installed-system counts or consumables revenue, which makes adoption harder to judge. Ribbon and Camena have real pharmaceutical relationships, but their commercial scale is less visible.
Which gene synthesis startup can scale production?
Elegen currently looks best prepared to handle rising centralized demand, while DNA Script has the most interesting model for spreading production across customer laboratories.
Elegen has already moved its newer manufacturing platform into commercial production. The resulting cost improvements were large enough to support lower prices, which is stronger evidence of scale than another laboratory demonstration.
Elegen also avoids building every regional commercial team itself. By selling through a major supplier, it can reach more customers without hiring a separate sales and support operation in every market. Simple, but important for a small biotechnology company.
Ansa is still building out its manufacturing base. The company disclosed that it was operating only a small number of production devices before its latest expansion push. Its recent financing should increase capacity, although public order-volume data have not yet shown the result.
DNA Script moves production to the customer. Each SYNTAX installation becomes a small local DNA factory, and the company can earn recurring revenue from reagents and support. That model could scale well if installations grow quickly. The missing figures are installed systems, utilization and repeat consumables purchases.
Ribbon’s in-lab kit follows a similar idea but remains in beta. Camena has expanded its facilities, although it still looks more like a specialist supplier than a high-volume manufacturing network.
This chart, featured in our synthetic biology market deck, compares the main business model options for synthetic biology platforms
Which gene synthesis startup is gaining ground fastest?
Ansa is gaining ground fastest right now, even though Elegen still leads the overall market.
Ansa has linked several developments that reinforce one another. It expanded its product range into much longer constructs, raised $54.4 million for manufacturing, promised free orders when qualifying delivery deadlines are missed and added a major distribution channel.
This is more substantial than a collection of unrelated announcements. Better technical capability created a broader product. The broader product required more capacity. The new capital and distribution agreement are now aimed at turning that capability into higher order volume.
Elegen’s recent progress has been more operational. It has broadened its product range, improved production economics and reduced prices. That is what a company does when it is moving from proving the technology to making the business work better.
Ribbon has also advanced quickly from a smaller base by launching cell-free commercial products and opening a beta programme for an in-lab kit. DNA Script has focused more on geographic expansion than on a major jump in synthesis length. Camena has added capital, facilities and a commercialization-focused chief executive, but those steps have not yet produced the same visible market change.
| Startup | Most important recent development | What it tells us |
|---|---|---|
| Ansa | New manufacturing capital, broader product range and guaranteed delivery | Fastest move from technical achievement toward larger commercial scale |
| Elegen | Better production economics and lower prices | Stronger execution inside an already commercial business |
| Ribbon Bio | Cell-free products and an in-lab beta kit | Rapid expansion from one platform into several product formats |
| DNA Script | New distributors across Asia and Latin America | Wider reach for an established instrument |
| Camena Bioscience | Larger facilities and new commercial leadership | Preparing for a broader launch |
| Evonetix | Few recent commercial milestones | Progress remains slower and less visible |
If you want more recent data on this point, please see our latest synthetic biology market report.
Which gene synthesis startup uses its funding best?
Elegen has produced the most commercial progress per disclosed dollar, while DNA Script has raised the most money without becoming the overall gene synthesis leader.
Elegen has publicly disclosed at least $35 million of financing and already sells several products, runs commercial manufacturing and works with major pharmaceutical and distribution partners. The exact funding total may be higher because early private rounds are not always fully reported, but the output remains strong for the capital disclosed.
DNA Script has raised about $315 million, far more than any direct rival. That money financed enzyme chemistry, protected nucleotides, fluidics, software and the development of a complete laboratory instrument. Hardware naturally costs more to develop than a centralized synthesis service.
The commercial result is still narrower than the funding gap suggests. SYNTAX can produce up to 384 short oligonucleotides in one run, but customers need additional assembly and verification to create a complete gene. Ansa and Elegen now deliver much longer finished DNA with far less disclosed capital.
Ribbon also looks efficient. With roughly $20 million of publicly documented investment, it has launched commercial cell-free DNA and an in-lab beta product. Camena has reached pharmaceutical partnerships with a smaller funding base, although its revenue and production data remain limited.
Evonetix presents the weakest visible funding conversion today. It has raised close to $70 million and built an ambitious semiconductor platform, but no broadly available commercial product has emerged.
Elegen’s latest price reduction strengthens its efficiency case. The company has converted technical development into a benefit customers can see directly.
This chart, featured in our synthetic biology market deck, illustrates the share of revenue generated by each customer segment in the synthetic biology market
Which gene synthesis startup has the strongest moat?
Ansa has the most distinctive core synthesis chemistry, while Elegen has built the strongest commercial moat around production, price and customer access.
Ansa’s enzyme-nucleotide conjugate system directly synthesizes complex DNA segments that are much longer than standard oligonucleotides. A competitor would need to reproduce the chemistry, the assembly process and the quality-control workflow before matching the final product.
Elegen’s defense is broader. Its advantage comes from cell-free manufacturing, error control, automation, process knowledge and the ability to sell difficult DNA at increasingly competitive prices. Copying one element would not immediately reproduce the whole system.
DNA Script may have the strongest hardware moat. Its instrument combines enzymes, surface chemistry, fluidics, software and consumables. Once a laboratory installs the system and trains staff, changing platform involves more than selecting another supplier from a website.
Evonetix has an even more unusual hardware architecture built around semiconductor-controlled reaction sites. The engineering barrier could become valuable, but a moat only helps commercially once the product reaches customers.
Ribbon and Camena rely on combinations of enzymatic chemistry, software and assembly knowledge. Their long-term position will depend on whether customer orders and manufacturing experience improve their platforms faster than competitors can copy them.
If you want more recent data on this point, please see our latest synthetic biology market report.
Could Twist, IDT or GenScript overtake the gene synthesis startups?
Twist, IDT and GenScript already dominate gene synthesis by revenue and customer reach, but startups still lead several technical frontiers that the incumbents have chosen to access through partnerships.
The scale gap is huge. Twist expects close to $200 million in annual DNA Synthesis and Protein Solutions revenue. GenScript’s Life Science business generates more than $500 million and serves tens of thousands of active users. IDT operates within Danaher and already supplies laboratories around the world.
No startup in this comparison has disclosed revenue anywhere near those levels. Elegen and Ansa lead in specific forms of long, difficult and cell-free DNA rather than in total orders or customer count.
IDT already distributes products from both companies. That relationship appears repeatedly for a reason: it shows one likely route to consolidation. IDT can add new capabilities quickly, while the startups gain global reach without recreating IDT’s sales network.
The danger is obvious. An incumbent could acquire a startup, license another technology or develop a competing process internally. A startup that depends too heavily on one large partner may also lose bargaining power.
Elegen and Ansa remain attractive because they offer capabilities the large suppliers do not appear able to reproduce quickly. Their lead would shrink fast if the incumbents matched the same lengths, complexity and delivery times at large-scale pricing.
This chart, featured in our synthetic biology market deck, shows how gene therapy technology has evolved over time
How reliable are gene synthesis startup claims?
Gene synthesis startup claims are reliable enough to identify the leaders, but the exact distance between them remains uncertain because the most useful commercial data stay private.
We can verify financing announcements, product specifications, published prices, partnerships and manufacturing launches. We usually cannot verify revenue, order volume, repeat purchasing, rejection rates, production yield or customer retention.
The language used by companies can blur comparisons. Ansa’s longest product is an assembled and verified construct rather than one continuous synthesis reaction. Elegen’s per-base accuracy measures something different from Ribbon’s percentage of sequence-correct molecules. DNA Script’s same-day synthesis refers to short oligonucleotides rather than a finished gene.
Most performance data also come from the company selling the technology. Major pharmaceutical customers and established suppliers provide some outside validation because they conduct technical checks before signing agreements. They still do not replace a neutral comparison across the same set of sequences.
Funding totals create another source of noise. Ansa’s reported cumulative capital changes depending on whether grants, debt and different financing closes are included. Ribbon and Elegen also have different totals across databases.
We therefore put the most weight on evidence that is hard to dress up: products that customers can order, prices they can see, delivery windows the company promises, production systems already in use and partnerships that put the product into real purchasing channels.
Which gene synthesis startups are actually ahead?
Elegen is the gene synthesis startup ahead overall today, with Ansa close behind and moving faster.
Elegen wins because it has built the best complete commercial package. Its products are available now, the specifications are clear, turnaround is competitive, prices have fallen and production has moved beyond the experimental stage.
Ansa takes second place but owns the strongest technical headline. It handles larger constructs and difficult sequences that sit outside the normal range of most competitors. Its recent push into manufacturing and guaranteed delivery gives it a realistic path to first place.
DNA Script ranks third as the clear leader in benchtop oligonucleotide synthesis. Its instrument is mature, well funded and increasingly international. The limitation is straightforward: customers still need more work before those short sequences become a complete gene.
Ribbon ranks fourth and has the best chance of entering the top three. Its cell-free 12 kb products and in-lab kit target the same difficult-DNA problem as Elegen and Ansa. Commercial adoption now matters more than another technical announcement.
Camena ranks fifth because its technology and pharmaceutical relationships are credible, but public product and scale data remain thin. Evonetix ranks sixth because its semiconductor platform has yet to become a broadly available product.
The current structure is a narrow top two, one strong specialist and three earlier challengers. Elegen leads the business today. Ansa is the company most likely to change that ranking.
| Rank | Startup | Why it ranks here |
|---|---|---|
| 1 | Elegen | Strongest mix of commercial maturity, speed, pricing, production readiness and customer access |
| 2 | Ansa Biotechnologies | Best ultra-long and difficult DNA capability, with the fastest recent commercial progress |
| 3 | DNA Script | Clear leader in decentralized oligonucleotide synthesis, but not yet in complete long genes |
| 4 | Ribbon Bio | Credible cell-free products and an interesting in-lab model, with less visible adoption |
| 5 | Camena Bioscience | Promising technology and pharmaceutical validation, but limited public scale data |
| 6 | Evonetix | Defensible semiconductor approach, but still waiting for broad commercial availability |
If you want more recent data on this point, please see our latest synthetic biology market report.
In our synthetic biology market deck, we identify pain points entrepreneurs should prioritize
OUR METHODOLOGY
This analysis asks which gene synthesis startup is ahead today. We compare six companies whose core business is custom DNA production: Elegen, Ansa Biotechnologies, DNA Script, Ribbon Bio, Camena Bioscience and Evonetix.
We assessed product maturity, maximum delivered DNA length, turnaround, quality claims, difficult-sequence capability, pricing, commercial traction, production scalability, recent momentum, capital efficiency and defensibility. Each dimension was reviewed separately before we combined the evidence into the final ranking.
We gave the most weight to operational evidence: products customers can order, published specifications, visible prices, promised delivery windows, manufacturing systems already in use and partnerships that expand real purchasing access. Financing announcements and broad technology claims were useful context, but they did not outweigh commercial delivery.
The comparison separates finished multi-kilobase DNA from short oligonucleotide synthesis. DNA Script’s SYNTAX platform is therefore treated as the leader in decentralized benchtop oligo production, not as a direct equivalent to the complete genes and constructs delivered by Elegen, Ansa or Ribbon.
Quality figures were not treated as interchangeable. Elegen reports per-base accuracy across a delivered DNA population, Ansa verifies a selected clonal construct against the requested sequence, and Ribbon reports the proportion of sequence-correct molecules. We compared the transparency and practical meaning of those claims rather than forcing them into one artificial score.
Funding figures use disclosed equity rounds where possible. Approximate totals are used when company announcements and private-market databases differ or when grants, debt and later undisclosed capital make a clean cumulative number impossible.
Key sources include Elegen’s ENFINIA Linear DNA specifications and pricing, Elegen’s GEN II production and pricing announcement, Elegen’s manufacturing technology overview, the Elegen–GSK collaboration and licensing announcement, Ansa’s 50 kb XL Clonal DNA specifications, Ansa’s standard Clonal DNA specifications, Ansa’s on-time delivery guarantee, Ansa’s financing and manufacturing updates, the IDT distribution agreement with Ansa, DNA Script’s SYNTAX product specifications, Ribbon Bio’s MiroSynth product specifications, Ribbon Bio’s commercial launch announcement, Camena Bioscience’s commercial and funding history, and Camena’s gSynth technology overview.
This chart, featured in our synthetic biology market deck, illustrates the share of revenue by region across Europe, Asia, North America, Africa, and South America in the synthetic biology market
Related blog posts
- Gene editing: which startup is ahead?
